当前位置： SCI文献检索 > CLINICAL DRUG INVESTIGATION期刊下所有文献 > Mecapegfilgrastim in Chemotherapy-Induced Neutropenia: A Profile of Its Use in China.

Mecapegfilgrastim in Chemotherapy-Induced Neutropenia: A Profile of Its Use in China.

Abstract：

:Mecapegfilgrastim (HHPG-19K) is a long-acting pegylated recombinant human granulocyte-colony stimulating factor (rhG-CSF) that is administered subcutaneously as prophylaxis once per chemotherapy cycle as a weight-adjusted dose of 100 µg/kg or as a 6 mg fixed dose. It is approved in China to reduce the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer therapy associated with a clinically significant incidence of febrile neutropenia. In phase III trials, once per cycle prophylaxis with mecapegfilgrastim was more effective than placebo in reducing the incidence of grade ≥ 3 neutropenia in cycle 1 in patients with advanced non-small cell lung cancer and was more effective than filgrastim at reducing the mean duration of grade ≥ 3 neutropenia in cycle 1 in patients with breast cancer. The tolerability and safety profiles of mecapegfilgrastim were similar to those of filgrastim, with no unexpected adverse events (AEs); most adverse reactions in cycle 1 were mild or moderate in severity. Thus, mecapegfilgrastim is an effective and generally well tolerated treatment option for patients with non-myeloid malignancies receiving myelosuppressive chemotherapy, and extends the options available for managing chemotherapy-induced neutropenia in China.

journal_name

Clin Drug Investig

journal_title

Clinical drug investigation

authors

Al-Salama ZT,Keam SJ

doi

10.1007/s40261-019-00836-y

subject

Has Abstract

pub_date

2019-10-01 00:00:00

pages

1009-1018

issue

10

eissn

1173-2563

issn

1179-1918

pii

10.1007/s40261-019-00836-y

journal_volume

39

pub_type

杂志文章,评审

相关文献

CLINICAL DRUG INVESTIGATION文献大全